±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1091  |  »Ø¸´: 24

peoplezz

¾èÖú¹ó±ö (СÓÐÃûÆø)


[½»Á÷] ´Ó¾­µäÀýÎÄÖÐѧϰӢÎÄÂÛÎÄд×÷£¨µÚ1ÆÚ£ºSemaglutide£©

´ó¼ÒºÃ£¬ÎÒÊÇÒ½Ò©ÐÐÒµµÄÒ»Ãû´ÓÒµÈËÔ±£¬ÒµÓàʱ¼ä»á´ÓÊÂһЩרҵ·­Òë·½ÃæµÄ¹¤×÷£¬¶Ï¶ÏÐøÐøÓм¸Äêʱ¼äÁË¡£

Æäʵ·­Òë²¢²»ÉñÃØ£¬×îÖØÒªÖ®´¦ÎÞ·ÇÊǶàÁ·¶à¿´£¬´ÓºÃµÄÎÄÕÂÖÐÌáÈ¡×îµØµÀµÄ±í´ï£¬ÈÚÈëµ½×Ô¼ºµÄ±í´ïÖ®ÖС£Òò´Ë£¬ÎÒ×ÜÊÇ»á³é³öºÜ¶àʱ¼ä½øÐÐһЩ·­ÒëµÄÁ·Ï°À´ÌáÉý×Ô¼º¡£

ÔÚ×öÁ·Ï°µÄʱ£¬ÎÒÓÐÒ»ÌìÏëµ½£¬¼ÈÈ»ÒѾ­×öÁËһЩ¹¤×÷£¬ÄÇôΪºÎ²»Í¬Ê±°ÑÕâЩ¹¤×÷ÄÚÈÝ·ÖÏí³öÀ´ÄØ¡£Ò»·½Ãæ¿ÉÒÔ°ïÖúÓÐÐèÇóµÄС»ï°é×ÔÎÒÌáÉý£¬Ò»·½ÃæÊÕµ½±ðÈ˵ãÆÀºÍÌáÎʶÔ×Ô¼ºÒ²ÊÇÒ»ÖÖÊÕ»ñ¡££¨ÔÚÕâÀï¸Ðл³ÂÊýÑòǰ±²¸øÎҵĴøÀ´µÄÆô·¢¡£ÁíÍ⣬±¾ÆªÎÄÕÂÖеĺܶàÄÚÈÝÒ²À´×ÔÊýÑòÀÏʦµÄ½Ìѧ·ÖÏí£©¡£

ÎÒ×öÁ·Ï°µÄ·½Ê½ÊǷdz£¡°±¿¡±µÄ£¬»áÏȰÑÎÄÕ·­Òë³ÉÖÐÎÄ£¬ÔÙ×Ô¼º·­Òë»ØÈ¥¶ÔÕÕÔ­ÎĽøÐÐѧϰ¡£±¾ÎĵĻط­Í³Ò»ÓÃÁË»úÆ÷·­Ò룬ËäÈ»ÔÚ×Ô¼º×öÁ·Ï°Ê±²»½¨ÒéÕâÑù×ö¡£ÁíÍâÏë˵һÏ£¬ÔÚ´ó¼Òд×÷¹ý³ÌÖл¹ÊǷdz£½¨ÒéÄÜÒÔ»úÆ÷·­Òë½á¹û×÷Ϊ²Î¿¼µÄ£¬ÒòΪÏÖÔڵĻúÆ÷·­ÒëˮƽÒѾ­±È½ÏÎȶ¨ºÍÓÅÐãÁË£¬Õ¾ÔÚËüµÄ¼ç°òÉÏ£¬¶ÔÂÛÎÄд×÷Óкܴó°ïÖú¡£ÄÇôÎÒÃÇÐèҪѧϰµÄÆäʵÊÇ£¬ÈçºÎÔÚ»úÆ÷·­ÒëÉϽøÒ»²½µÄÌá¸ß×Ô¼º¡£

½ñÌìÒª·ÖÏíµÄһƪÎÄÕ½ÚÑ¡×Ô˾ÃÀ¸ñ³ëĵÄÁÙ´²ÊÔÑéÂÛÎÄ£ºTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial¡£

˾ÃÀ¸ñ³ëÄ£¨semaglutide£©Êǵ¤ÂóŵºÍŵµÂ¹«Ë¾£¨Novo Nordisk£©ÕâÁ½Äê´ó»ðµÄ²úÆ·£¬Ö÷Òª×÷ÓÃÊÇ´Ù½øÒȵºËØ·ÖÃÚ¡£ÒȵºËØ¿ÉÒÔ½µµÍѪÌÇ£¬ÓÃÓÚÖÎÁÆÌÇÄò²¡£¬Ò²¿ÉÒÔÓÃÓÚ¼õ·Ê¡£

¹ØÓÚsemaglutideµÄÁÙ´²ÊÔÑéÊÇһϵÁеģ¬Ä¿Ç°ÒѾ­ÓÐ8¸ö¹ØÓÚsemaglutideµÄÁÙ´²ÊÔÑé½áÊøÇÒ·¢²¼Á˽á¹û£¬Ïà¹ØÎÄÕ»ù±¾¶¼·¢±íÔÚҽѧ¶¥¿¯ÉÏ£¬ÎÒÃÇÒªÌÖÂÛµÄÕâÆªÀ´×ÔNature Medicine¡£

ÄǺóÃæ¾ÍÈÃÎÒÃÇÀ´¿´Ò»¿´ÎÄÕÂÖеÄÕâЩµØµÀ±í´ï°É£¡

£¨ÄúµÄÖ§³ÖºÍ¹ÄÀøÊÇÎÒǰ½øµÄ¶¯Á¦¡£Èç¹ûϲ»¶µÄÅóÓÑÃǶ࣬ÎÒºóÐø»á³ÖÐø¸üв»Í¬µÄÄÚÈÝ¡£ÄúÈç¹ûÓбȽϺõÄÏëÒªÒ»ÆðÔĶÁѧϰµÄÎÄÕ£¬Ò²¿ÉÒÔ¸æËßÎÒ£¬ÎÒÃÇÒ»Æðѧϰ½ø²½¡£ÓÉÓÚÆª·ùÔ­Òò£¬×îºÃÊÇÊÔÑéÀàÎÄÕ²»ÒªÊÇ×ÛÊöŶ¡££©
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
»ØÌûÖ§³Ö ( ÏÔʾ֧³Ö¶È×î¸ßµÄǰ 50 Ãû )

peoplezz

¾èÖú¹ó±ö (СÓÐÃûÆø)


Main²¿·Ö



°üÀ¨¸Ä±äÒûʳºÍÉíÌå»î¶¯µÄÐÐΪ¸ÉÔ¤ÈÔÈ»ÊÇÖÎÁƳ¬ÖغͷÊÅֵĻù´¡¡£



Ô­ÎÄ£ºBehavioral intervention incorporating modifications in diet and physical activity remains the foundation of treatment for overweight and obesity.



ÒëÎÄ£ºBehavioral intervention combined with diet change and physical activity is still the basis for the treatment of overweight and obesity.



1.    "incorporating" Ç¿µ÷ÕûºÏ»òºÏ²¢£¬Ê¹Ä³Îï³ÉΪÕûÌåµÄÒ»²¿·Ö£¬ÓÐÄÉÈëµÄÒâ˼£¬¶ø "combined with" ¸ü¶àµØÃèÊöÁ½¸ö»ò¶à¸öÔªËØÏ໥½áºÏ£¬"including" ¸ü¶àµØ±íʾÁоٻò¼òµ¥µØÌí¼ÓÄ³Ð©ÔªËØ£¬¶ø²»Ò»¶¨ÒªÓëÆäËû²¿·Ö½ôÃܽáºÏ¡£Õ⼸¸ö´Ê¶¼¿ÉÒÔ·­ÒëΪ°üÀ¨£¬½áºÏ¡£Èç¹ûÊdzöÏÖÔÚҽѧ²©Ê¿¿¼ÊÔÖУ¬ÄÇ´ó¸ÅÂÊ»áÔÚÑ¡ÔñÌâÖÐÑ¡ÔñÒ»¸öÌæ»»´Ê£¬±ÈÈçinclude¡£Á½ÕßÊǽüÒå´Ê£¬²»¹ýincorporateÓиüÃ÷ÏԵġ°ÄÉÈ롱Òâ˼£¬¶øinclude¾ÍÖ»ÊÇ¡°°üº¬¡±¡£±ÈÈçÔÚÕâ¾ä»°ÖУ¬ÐÐΪ¸ÉÔ¤¡°ÄÉÈ롱ÁËÒûʳºÍ»î¶¯³ÉΪһ¸öÕûÌ壬ÔÚ¾ßÌå±í´ïʱ¿ÉÒÔÖ±½Ó·­ÒëΪ¡°°üº¬/°üÀ¨¡±¡£

2.    "modifications in" ÍùÍùÃèÊö΢СµÄµ÷Õû£¬¶ø "change" ÊÇÒ»¸ö¸üΪÆÕ±éµÄÊõÓÓÃÓÚÃèÊö´Ó΢Сµ½ÏÔÖøµÄÈκα仯»òת±ä¡£¿ÉÒÔ»¥ÏàÌæ»»¡£

3.    "remains"ºÍ"is still"ÕâÁ½¸ö¶ÌÓﶼǿµ÷ijÖÖ״̬»òÇé¿öµÄ³ÖÐøÐÔ¡£µ«"remains" ÓÐʱ¸øÈËÒ»ÖÖÉÔ΢ÕýʽµÄ¸Ð¾õ£¬¶ø "is still" ÔÚÈÕ³£¶Ô»°ÖпÉÄܸüΪ³£¼û¡£¿ÉÒÔ»¥ÏàÌæ»»¡£

4.    "foundation" ͨ³£Ç¿µ÷ijʵĺËÐÄÔ­Ôò£¬ÓлùʯµÄº¬Ò壬¶ø "basis" ÔòÇ¿µ÷Âß¼­¡¢Ô­Òò»òÖ¤¾Ý¡£Ò²¿ÉÒÔ»¥ÏàÌæ»»¡£





È»¶ø£¬ÓÉÓÚÐÐΪ¸ÉԤͨ³£ÓëÁÙ´²ÉÏÓÐÒâÒåºÍ¿É³ÖÐøµÄÌåÖØ¼õÇáÎ޹أ¬Òò´Ë½¨Ò齫ҩÎïÖÎÁÆ×÷ΪÌåÖØÖ¸Êý£¨BMI£©ÖÁÉÙΪ 30 kg m-2 »ò»¼ÓÐÌåÖØÏà¹Ø¹²²¡Ö¢ÖÁÉÙΪ 27 kg m-2 µÄÈËȺ³¤ÆÚÌåÖØ¹ÜÀíµÄ¶îÍâÊֶΡ£

Ô­ÎÄ£ºHowever, because behavioral intervention is often not associated with clinically meaningful and sustainable weight loss, pharmacotherapy is recommended as an additional tool for long-term weight management in people with a body mass index (BMI) of at least 30 kg m¨C2, or at least 27 kg m¨C2 in those with weight-related comorbidities.



ÒëÎÄ£ºHowever, since behavioral interventions are usually not associated with clinically meaningful and sustainable weight loss, it is recommended that drug therapy be used as an additional tool for long-term weight management of people with a body mass index (BMI) of at least 30 kgm-2 or with weight related comorbidities of at least 27 kgm-2.



1.    "because" ¸üÖ±½Ó£¬¶ø "since" ÔòÓÐÒ»ÖÖ»ùÓÚÒÑÖª»ò¹«ÈÏÊÂʵµÄº¬Òå¡£Á½ÕßÔÚ´Ë¿ÉÒÔ»¥»»¡£

2.    ÁíÍâѧϰһÏ¡°it is recommended that ¡­ be used as ¡­¡± ¿ÉÒÔд³É ¡°¡­ is recommended as ¡­¡±

3.    ÓÐͳ¼ÆÑ§ÒâÒåµÄ¡°ÒâÒ塱Óà significant/significance »ù±¾ÊÇÔ¼¶¨Ë׳ɵÄÓ÷¨£¬µ«ÓÐÁÙ´²ÒâÒåµÄ¡°ÒâÒ塱ӢÓïÓôʻ¹²»ÄÇôͳһ£¬¿ÉÒÔ¼ûµ½Óà significant/significance¡¢meaningful/meaningfulness¡¢important/importance µÈ¡£Í¬Ê±£¬clinically/clinical »¹¿ÉÓà practically/practical »òÕß medically/medical µÈ¡£

4.    Ò©ÎïÁÆ·¨/ÖÎÁÆÒ»°ã¿ÉÄܱȽÏÏëµ½µÄ±í´ïÊÇdrug treatment/therapy£¬Ò²¿ÉÒÔÓÃpharmacotherapyÌæ»»¡£ÔÚ±íʾ¡°½¨Ò顱µÄʱºò£¬Ò»°ãÎÒÃÇ»áÏëµ½adviceºÍsuggest£¬µ«ºÜ¶àʱºòÎÒÃÇÒ²¿ÉÒÔÓÃrecommendÍÆ¼öÌæ»»£¬¶øÇÒ´Ó˵»°×Ë̬ÉϸüƽµÈһЩ¡£

5.    as an additional tool£¬Õâ¸ö±í´ïÒ²¼Çһϣ¬ÖÐÎij£Óöµ½¡°×÷Ϊ¡­¡­²¹³ä/ÆäËûXX·½·¨/ÊֶΡ±£¬ÎÒÃǵ±È»¿ÉÒÔÓÃas a complementary/supplementary XX method/approach£¬Ò²¿ÉÒÔÓÃadditional tool¡£





Semaglutide ÊÇÒ»ÖÖÒȸßѪÌÇËØÑùëÄ-1£¨GLP-1£©ÀàËÆÎ±»Åú×¼ÓÃÓÚÖÎÁƶþÐÍÌÇÄò²¡£¨¿Ú·þ Semaglutide ºÍƤÏÂ×¢Éä Semaglutide£©ºÍ½µµÍ¶þÐÍÌÇÄò²¡ºÍÐÄѪ¹Ü¼²²¡»¼ÕßµÄÐÄѪ¹Üʼþ·çÏÕ£¨½öƤÏÂ×¢Éä Semaglutide£©¡£



Ô­ÎÄ£ºSemaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for the treatment of type 2 diabetes (oral semaglutide and subcutaneous semaglutide) and for reducing the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease (subcutaneous semaglutide only).



ÒëÎÄ£ºSemaglutide is a glucagon like peptide-1 (GLP-1) analog, which is approved for the treatment of type 2 diabetes mellitus (oral semaglutide and subcutaneous semaglutide) and reducing the risk of cardiovascular events in patients with type 2 diabetes mellitus and cardiovascular disease (subcutaneous semaglutide only).



1.    Õâ¶Î·­ÒëµÄ·Ç³£ºÃ£¬Ö»ÊÇ approved for ÈçÊ¡ÂÔ which is ¿ÉÂÔÏÔ¼ò½à¡£Ò½Ñ§ÀàÂÛÎÄ/²úÆ·Ñо¿Öо­³£³öÏÖFDA approvedºÍFDA cleared£¬ËüÃÇÁ½¸öÓÐÊ²Ã´Çø±ðÄØ£¿approved±ÈclearedÒªÇó¸ü¸ß£¬±ÈÈçÔÚÒ©ÎïÉÏ£¬±ØÐëÒªÖ¤Ã÷°²È«ÐÔºÍÓÐЧÐÔ£¬²Å¿ÉÒÔapproved£¬approvedºóµÄ²úÆ·Ò²Òâζ×Å»ñÒæ±ÈÒÑÖª·çÏÕ´ó¡£¶øclearedÒ»°ãÊÊÓÃÓÚ¸úÏÖÓвúÆ·ÏàËÆµÄвúÆ·£¬¶ø²»Ò»¶¨ÊÇͨ¹ýÁ˶ÀÁ¢µÄ°²È«ÐÔÊÔÑ顣˵µ½ÕâÀÓÐʱºò¿ÉÄÜ»¹»á¿´µ½FDA registeredºÍFDA certificated£¬ÕâÁ½¸ö±í´ï¸úFDAµÄÈÏ¿ÉûÓÐʲô¹ØÏµ£¬Èç¹ûij¸ö²úÆ·ÓÃÁËÕâЩ±í´ïÐû´«£¬ÄÇ´ó¸ÅÂʾÍÊÇÉú²úÉÌҪƭÈËÁË¡£





¸ù¾Ý semaglutide ¶Ô·ÊÅÖ»¼ÕßµÄÖÎÁÆÐ§¹û£¨STEP£©ÁÙ´²ÊÔÑ鼯»®µÄ½á¹û£¬ÃÀ¹ú¡¢Å·ÖÞ¡¢Ó¢¹úºÍ¼ÓÄôóÅú׼ƤÏÂ×¢Éä semaglutide£¬¼ÁÁ¿Îª2.4 mg£¬Ã¿ÖÜÒ»´Î£¬ÓÃÓÚ³¬ÖØ£¨BMI¡Ý27 kg m-2£¬ÖÁÉÙÓÐÒ»ÖÖÌåÖØÏà¹Ø¹²²¡Ö¢£©»ò·ÊÅÖ£¨BMI¡Ý30 kg m-2£©µÄ³ÉÈ˵ÄÌåÖØ¹ÜÀí¡£



Ô­ÎÄ£ºAt a dose of 2.4 mg once-weekly, subcutaneous semaglutide was approved in the United States, Europe, the United Kingdom and Canada for weight management in adults with overweight (BMI ¡Ý 27 kg m¨C2 with at least one weight-related comorbidity) or obesity (BMI ¡Ý 30 kg m¨C2), based on results from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program.



ÒëÎÄ£ºAccording to the results of the treatment effect of semaglutide on obese patients (step) clinical trial plan, the United States, Europe, the United Kingdom and Canada approved the subcutaneous injection of semaglutide at a dose of 2.4 mg once a week for the weight management of overweight (BMI ¡Ý 27 kgm-2, at least one weight related comorbidity) or obese (BMI ¡Ý 30 kgm-2) adults.



1.    Õâ¾ä»°Óôʶ¼Ã»ÓÐʲôÎÊÌ⣬µ«ÊÇ·¸ÁË»úÆ÷·­ÒëºÍ²»ÉÙˮƽ²»´íÒëÕß·­ÒëÖÐ×î³£¼ûµÄ벡£¬ÄǾÍÊǽé´Ê¶ÌÓï±È½Ï¶àµÄʱºòÅÅÐòϰ¹ß»¹Êǰ´ÕÕÖÐÎĵÄÀ´£¬Ïà¶ÔÖØÒªµÄ²¿·Ö·ÅµÄÌ«¿¿ºóÁË£¬Òò´Ë·­ÒëÏÂÀ´´øÓÐŨŨµÄÖÐʽӢÓï·ç¸ñ£¬ÁíÍâÖ÷Òª½á¹¹Ò²Ã»ÓÐÓøü·ûºÏÓ¢Óï±í´ïϰ¹ßµÄ±»¶¯Óï̬¡£Õâ¾ä»°Óа˸ö½é´Ê¶ÌÓAt a dose of 2.4 mg once-weekly£¬in the United States¡­£¬in adults£¬with overweight£¬with at least one weight-related comorbidity£¬or obesity£¬based on results£¬from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program£¬Ò»¶¨Òª¶à¶àÕå×ã¬ÊìϤÆäÅÅÐòµÄÓ¢Óï±í´ïϰ¹ß¡£

2.    managementÒ²¿ÉÒÔ¶à¹Ø×¢Ò»Ï£¬ÓÐʱºò¿ÉÒÔÌæ»»control£¬±ÈÈçѪѹ¿ØÖÆ blood pressure control£¬Ò²¿ÉÒÔ»»´Êblood pressure management¡£





ÔÚûÓÐ 2 ÐÍÌÇÄò²¡µÄ²ÎÓëÕßµÄ STEP 1 ºÍ 3 ÊÔÑéÖУ¬Ê¹Óà semaglutide 2.4 mg ¹Û²ìµ½Æ½¾ù¼õÈ¥°²Î¿¼ÁµÄÌåÖØ¼õÇáÔÚ 68 ÖÜ·Ö±ðΪ 12.4% ºÍ 10.3% ¡£



Ô­ÎÄ£ºIn the STEP 1 and 3 trials in participants without type 2 diabetes, average placebo-subtracted weight losses of 12.4% and 10.3%, respectively, were seen with semaglutide 2.4 mg at week 68.



ÒëÎÄ£ºIn the STEP 1 and 3 trials of participants without type 2 diabetes, using semaglutide 2.4 mg, we observed that the average weight loss after subtracting placebo was 12.4% and 10.3% at 68 weeks, respectively.



1.    Õâ¾ä»°ÓÖÊÇÒ»¸öºÜºÃµÄ·¶Àý£¬±í´ïÉÏËäȻûʲôÎÊÌ⣬µ«ÊDZí´ï´øÓÐō֨µÄÖÐÎÄϰ¹ß¡£×¢Ò⣬Óñ»¶¯Óï̬°ÑÒª±í´ïµÄÖØµãÌáǰ£¡

2.    "seen"Ö÷ÒªÓë¼òµ¥µÄÊÓ¾õ¸ÐÖªÓйأ¬¶ø "observed" ³ýÁ˱íʾ¿´µ½Í⣬»¹´øÓиüÉîÈë¡¢×Ðϸ»òרҵµÄ¹Û²ìµÄº¬Òå¡£Õâ¾ä»°²Î¿¼ÒëÎĵÄÓôʱíÏÖÉõÖÁ¸üºÃһЩ¡£





STEP ÊÔÑéÏîÄ¿ÖÐÏÈǰµÄÑо¿½öÏÞÓÚ³¤´ï 68 ÖܵÄÖÎÁƳÖÐøÊ±¼ä¡£



Ô­ÎÄ£ºPrevious studies in the STEP trial program have been limited to treatment durations of up to 68 weeks.



ÒëÎÄ£ºPrevious studies in the STEP trial were limited to treatment duration of up to 68 weeks.



1.    Õâ¾ä»°ÓÐÁ½¸ö¹Ø×¢µã£¬Ò»¸öÊÇʱ̬£¬Ò»¸öÊǵ¥¸´Êý¡£Èç¹ûÓÃÏÖÔÚÍê³Éʱ£¬±íʾ STEP Ñо¿»¹ÔÚ¼ÌÐø£¬Ã»ÓнáÊø¡£Óùýȥʽ±íʾ STEP Ñо¿ÒѾ­Íê³É¡£ÕâÀïҪעÒâÇø·Öһϵ½µ×ÐèÒªÓÃÄÄÖÖʱ̬±í´ï¡£ÁíÍâÎÄÖÐÓÃÁË up to Òâ˼Ϊ×î¸ß´ïµ½£¬²»Í¬ÊÔÑéµÄ treatment duration ÊDz»Í¬µÄ£¬ÕâÀïÓ¦¸ÃÓø´Êý¡£





±¾Îı¨µÀµÄ STEP 5 Ñо¿ÎªÆÚ 2 Äּ꣬ÔÚÆÀ¹ÀÿÖÜÒ»´ÎƤÏÂ×¢Éä 2.4 mg semaglutide Ó밲ο¼ÁÏà±È£¬×÷ΪÐÐΪ¸ÉÔ¤µÄ¸¨ÖúÊֶΣ¬Õë¶Ô·ÊÅÖ£¨BMI ¡Ý 30 kg/m² £©³ÉÄêÈË£¬»ò³¬ÖØ£¨BMI ¡Ý 27 kg/m² £©³ÉÄêÈË£¬ÇÒÖÁÉÙ´æÔÚÒ»ÖÖÓëÌåÖØÏà¹ØµÄ¹²²¡Ö¢ÇÒûÓÐÌÇÄò²¡£¬¶ÔÌåÖØºÍÐÄѪ¹Ü´úл·çÏÕÒòËØµÄ³¤ÆÚÓ°Ïì¡£



Ô­ÎÄ£ºThe 2-year STEP 5 study reported herein was conducted to evaluate the long-term effect of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo, as an adjunct to behavioral intervention, on body weight and cardiometabolic risk factors, in adults with obesity (BMI ¡Ý 30 kg m¨C2), or with overweight (BMI ¡Ý 27 kg m¨C2) and at least one weight-related comorbidity, without diabetes .



ÒëÎÄ£ºThe 2-year step 5 study reported in this paper aims to evaluate the long-term impact of weekly subcutaneous injection of 2.4 mg semaglutide on weight and cardiovascular metabolic risk factors in obese (BMI ¡Ý 30 kg/M ² or overweight (BMI ¡Ý 27 kg/m ² ) adults with at least one weight related comorbidity and no diabetes compared with placebo.



1.    ѧϰһÏ herein µÄʹÓ㬿ÉÒÔ´úÌæ here£¬in this paper£¬in this study µÈ±í´ï¡£Ô­ÎÄÔÚÕâ¶Î»°µÄ´¦ÀíÉϸü¼ò½à£¬ÊÇÎÒÃÇÐèҪѧϰµÄµØ·½¡£

2.    "was conducted to" ÃèÊöÁËÒѾ­·¢ÉúµÄÊÂÇéµÄÄ¿µÄ£¬¶ø "aims to" ÃèÊöÁËÏÖÔÚ»òδÀ´µÄ¼Æ»®»ò»î¶¯µÄÄ¿±ê¡£¹ýȥʱ̬µÄ±»¶¯Óï̬¸ü·ûºÏÎÄÕÂÒâ˼ºÍÓ¢Óïϰ¹ß¡£

3.    Cardiometabolic Óë cardiovascular metabolic£¬¾­¹ý²éÖ¤£¬ºóÕ߸ü³£¼ûһЩ£¬µ«Ç°ÕßÊÇÒ»¸öרÓÐÃû´Ê¡£Òò´ËÔÚ×öרҵ´Ê»ã²éÖ¤µÄʱºòÐèÒª×Ðϸ¡£

4.    "impact" ÍùÍù´øÓиüÇ¿ÁÒ»ò¸üÖ±½ÓµÄÓ°ÏìµÄº¬Ò壬¶ø "effect" ¸üΪÖÐÐÔ£¬Ö¸µÄÊÇij¸öÔ­ÒòµÄÖ±½Ó½á¹û»òºó¹û¡£ÔÚÕâÀïµÄÓ°ÏìÓà effect ¸üºÃЩ£¬¿ÉÒÔÓë±êÌâºôÓ¦¡£

5.    Without ºÍ and no ¶¼¿ÉÒÔÓÃÔÚÕâÀï¡£

6.    Õâ¾ä»°ÓÐÊ®¸ö½é´Ê¶ÌÓï¡£ÒëÎĵıíÏÖ¿ÉÒÔ˵Ï൱²»´í£¬Ö»Ðèµ÷Õûcompared with placebo µÄλÖã¬ÁíÍâ×öһЩ±í´ïÉϵÄС΢µ÷¡£





ÕâÏî3ÆÚ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕ¡¢¶à¹úÊÔÑé´ú±íÁËÆù½ñΪֹʹÓà semaglutide ½øÐÐÌåÖØ¹ÜÀíµÄ×Ñо¿¡£



Ô­ÎÄ£ºThis phase 3, randomized, double-blind, placebo-controlled, multinational trial represents the longest study of the use of semaglutide for weight management to date.



ÒëÎÄ£ºThis phase 3, randomized, double-blind, placebo-controlled, multinational trial represents the longest study of weight management using semaglutide to date.



1.    Õâ¾ä»°±È½Ï¼òµ¥£¬ÒëÎĵÄÍê³É¶ÈºÜ¸ß¡£to dateѧϰһÏ£¬¡°½ØÖ¹µ½Ä¿Ç°¡±¡£

2.    Õâ¾ä»°Ö»ÓÐÒ»µãС覴㬾ÍÊÇÒª°ÑÖØµã¡°Ê¹Óà semaglutide ½øÐС±·ÅÔÚǰ±ß¡£ÕâÑù¾ÍºÍÔ­ÎÄÍêȫһÖÂÁË¡£





¹²Í¬Ö÷ÒªÖÕµãÊÇ´Ó»ùÏßµ½µÚ 104 ÖÜÌåÖØµÄ°Ù·Ö±È±ä»¯£¬ÒÔ¼°ÔÚµÚ 104 ÖÜÌåÖØ¼õÇá³Ì¶ÈÖÁÉÙΪ»ùÏßÌåÖØµÄ 5%¡£



Ô­ÎÄ£ºCo-primary endpoints were percentage change in body weight from baseline to week 104 and achievement of weight loss of at least 5% of baseline weight at week 104.



ÒëÎÄ£ºThe common primary endpoint was the percentage change in body weight from baseline to week 104 and a weight loss of at least 5% of baseline body weight at week 104.



1.    ÒëÎÄÔÚÕâÀï·¸ÁËÒ»¸ö±È½Ï´óµÄ´íÎ󣬹²Í¬Ö÷ÒªÖÕµã Co-primary endpoints ·­Òë³ÉÁ˹²Ê¶ÖеÄÖ÷ÒªÖÕµã common primary endpoint¡£ËùÒÔרҵ´Ê»ã×îºÃ·´¸´Ð£¶Ô¡£

2.    ÒëÎĵ¥¸´ÊýÓôíÁË¡£ÓÉÓÚÖÐÎÄϰ¹ß²»Çø·Öµ¥¸´Êý£¬Òò´ËÒëÎÄÖÐÈÝÒ׳ö´í£¬ÐèҪСÐÄ¡£

3.    weight loss ǰ¼ÓÈë achievement ¿ÉÒÔʹ±í´ï¸üµØµÀ£¬ºôÓ¦percentage change in body weight¡£ÔÚÓ¢Îıí´ïʱºòҪѧ»á¼ÓÉÏÕâЩʵ¼Êº¬Òå²»´óµ«È´Ó°ÏìÕûÌå¹Û¸ÐµÄ´Ê»ã¡£
21Â¥2023-09-16 17:49:54
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

peoplezz

¾èÖú¹ó±ö (СÓÐÃûÆø)


7Â¥2023-09-15 21:28:05
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
ÈfÊÂÈçÒâ
5Â¥2023-09-15 20:53:13
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

chenhuanlong

½û³æ (ÎÄѧ̩¶·)

¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
±¾ÌûÄÚÈݱ»ÆÁ±Î

10Â¥2023-09-15 22:37:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

haisheng1792

гæ (ÎÄ̳¾«Ó¢)


¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
11Â¥2023-09-15 22:49:56
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

liunahan

ľ³æÖ®Íõ (ÎÄѧ̩¶·)


¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
19Â¥2023-09-16 14:18:36
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gdflly08

ľ³æ (ÎÄ̳¾«Ó¢)


¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
´Ó¾­µäÀýÎÄÖÐѧϰӢÎÄÂÛÎÄд×÷
24Â¥2023-09-16 21:41:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
2023-09-15 19:06   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
·¢×ÔСľ³æAndroid¿Í»§¶Ë
tzynew3Â¥
2023-09-15 19:16   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
l ·¢×ÔСľ³æAndroid¿Í»§¶Ë
yuekong4Â¥
2023-09-15 20:32   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
·¢×ÔСľ³æAndroid¿Í»§¶Ë
hyjcs6Â¥
2023-09-15 21:05   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
ภ·¢×ÔСľ³æAndroid¿Í»§¶Ë
psylhh8Â¥
2023-09-15 21:28   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
anita*9Â¥
2023-09-15 21:33   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
·¢×ÔСľ³æIOS¿Í»§¶Ë
2023-09-16 00:48   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
л ·¢×ÔСľ³æIOS¿Í»§¶Ë
¼Ù´ó¿Õ13Â¥
2023-09-16 09:43   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
68041614Â¥
2023-09-16 09:46   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
·¢×ÔСľ³æIOS¿Í»§¶Ë
2023-09-16 10:09   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
·¢×ÔСľ³æAndroid¿Í»§¶Ë
xishandian16Â¥
2023-09-16 10:50   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
xishandian17Â¥
2023-09-16 11:01   »Ø¸´  
nono200918Â¥
2023-09-16 13:06   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
¡¤
2023-09-16 15:43   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
hoikisu22Â¥
2023-09-16 18:04   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
×£¸£ ·¢×ÔСľ³æIOS¿Í»§¶Ë
ÐÀÕÜ-21123Â¥
2023-09-16 20:34   »Ø¸´  
peoplezz(½ð±Ò+5): лл²ÎÓë
wukongbb25Â¥
2023-12-25 10:27   »Ø¸´  
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ peoplezz µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 291Çóµ÷¼Á +12 hhhhxn.. 2026-03-23 18/900 2026-03-27 17:41 by ditto77778
[¿¼ÑÐ] 340Çóµ÷¼Á +4 jhx777 2026-03-27 4/200 2026-03-27 16:50 by sanrepian
[¿¼ÑÐ] 317Çóµ÷¼Á +5 Ê®ÏÐwx 2026-03-24 5/250 2026-03-27 13:48 by ÑîÑîÑî×Ï
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ²ÄÁÏÓ뻯¹¤ 264·Ö¸÷¿Æ¹ýAÇø¹ú¼ÒÏß +10 ¹þ¹þ157349 2026-03-21 10/500 2026-03-27 13:06 by zzll406
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¶«Àí¹¤´óѧ081700£¬³õÊÔ·ÖÊý271 +6 kotoko_ik 2026-03-23 7/350 2026-03-27 12:29 by »ÝÖÝÅíÓÚêÌ
[¿¼ÑÐ] 333Çóµ÷¼Á +3 questionÍì·ç 2026-03-23 3/150 2026-03-27 11:29 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +3 ´Þwj 2026-03-26 3/150 2026-03-27 07:58 by chemisry
[¿¼ÑÐ] 341Çóµ÷¼Á +7 ÇàÄûÃÊ1 2026-03-26 7/350 2026-03-27 00:19 by wxiongid
[¿¼ÑÐ] 071000ÉúÎïѧÇóµ÷¼Á£¬³õÊԳɼ¨343 +6 ССÌðÃæÍÅ 2026-03-25 6/300 2026-03-26 23:01 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] Ò»Ö¾Ô¸±±»¯Çóµ÷¼Á +3 Jsman 2026-03-22 3/150 2026-03-26 21:06 by ajpv·çÀ×
[¿¼ÑÐ] ²ÄÁϵ÷¼Á 5+4 ÏëÒªÒ»ºøÌÒ»¨Ë® 2026-03-25 10/500 2026-03-26 19:56 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] ѰÕÒµ÷¼Á +5 ¾óǿâ? 2026-03-21 8/400 2026-03-26 13:25 by 0906ljy
[¿¼ÑÐ] ÍøÂç¿Õ¼ä°²È«0839Õе÷¼Á +4 w320357296 2026-03-25 6/300 2026-03-25 17:59 by 255671
[¿¼ÑÐ] ¸÷λÀÏʦÄúºÃ£º±¾È˳õÊÔ372·Ö +5 jjÓ¿77 2026-03-25 6/300 2026-03-25 14:15 by mapenggao
[¿¼ÑÐ] 340Çóµ÷¼Á +5 »°Ã·ÌÇ111 2026-03-24 5/250 2026-03-25 06:53 by ilovexiaobin
[¿¼ÑÐ] Ò»Ö¾Ô¸ÎäÀí085500»úеרҵ×Ü·Ö300Çóµ÷¼Á +3 an10101 2026-03-24 7/350 2026-03-25 00:00 by ɽ¹í0-
[¿¼ÑÐ] 292Çóµ÷¼Á +4 ¶ì¶ì¶ì¶î¶î¶î¶î¶ 2026-03-24 4/200 2026-03-24 16:41 by peike
[¿¼ÑÐ] Ò»Ö¾Ô¸ºÓ±±¹¤Òµ´óѧ0817»¯¹¤278·ÖÇóµ÷¼Á +7 jhybd 2026-03-23 12/600 2026-03-24 09:03 by jhybd
[¿¼ÑÐ] ÉúÎïѧµ÷¼Á +5 Surekei 2026-03-21 5/250 2026-03-22 14:39 by tcx007
[¿¼ÑÐ] ²ÄÁÏ 271Çóµ÷¼Á +5 Õ¹ÐÅÔÃ_ 2026-03-21 5/250 2026-03-21 17:29 by ѧԱ8dgXkO
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û